Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy : Future Perspectives |
Autore | Vermehren Charlotte |
Pubbl/distr/stampa | Basel, : MDPI Books, 2022 |
Descrizione fisica | 1 electronic resource (224 p.) |
Soggetto topico |
Medicine
Pharmaceutical industries |
Soggetto non controllato |
acute kidney injury
early biomarker plasma neutrophil gelatinase-associated lipocalin soluble urokinase plasminogen activator receptor medication optimization older patients emergency department multimorbidity polypharmacy potentially inappropriate medication use older adults prevalence determinants chronic outpatient 2019 Beers criteria Ethiopia pharmacogenomics persons with diabetes drug–drug interactions drug–gene interactions cytochrome P450 SLCO1B1 drug interaction checkers adverse drug reactions pharmacogenetics personalized medicine phenprocoumon DOACs bleeding thromboembolism HLA drug hypersensitivity abacavir allopurinol flucloxacillin antiepileptic drugs cost-effectiveness shared medication record medication reconciliation drug information service hospital pharmacy service electronic prescribing electronic medical record clinical pharmacist CYP2D6 CYP2D7P CYP2D8P copy number variation CNV genotyping 5’nuclease assay HRM high resolution melting drug metabolization extracellular vesicles exosomes microvesicles pharmacogene expression medication review deprescriptions quality of life aged aged, 80 and over nursing homes deprescribing medication-based risk score health outcomes cytochromes CYP1A2 adverse drug reaction antipsychotics olanzapine clozapine loxapine children youth digital decision-support health services research general practice process evaluation antidepressants utility population-based appropriateness medication adherence digital health |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Altri titoli varianti | Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
Record Nr. | UNINA-9910595072903321 |
Vermehren Charlotte | ||
Basel, : MDPI Books, 2022 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer |
Autore | Ferroni Patrizia |
Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
Descrizione fisica | 1 electronic resource (202 p.) |
Soggetto topico |
Medicine
Oncology |
Soggetto non controllato |
multiple myeloma
venous thromboembolism risk assessment models thromboprophylaxis direct oral anticoagulants cancer-associated venous thromboembolism thrombosis pulmonary embolism neoplasms anticoagulants coumarins low molecular weight heparins cancer endogenous heparin heparanase heparan sulfate hospice palliative care units low molecular weight heparin deep vein thrombosis cancer associated thrombosis VTE malignancy direct oral anticoagulant pancreatic cancer low-molecular weight heparin survival coagulation activation locally advanced breast cancer prognostic model pCR treatment prophylaxis DOAC simultaneous care integrated care lymphoma Non-Hodgkin lymphoma Hodgkin lymphoma risk factors molecular subtype arterial thrombosis ALK ROS1 KRAS chemotherapy low-molecular-weight heparin (LMWH) VKA UFH DOACs |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910585935803321 |
Ferroni Patrizia | ||
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|